ARG1 and neoplasm: Mechanistically, p300-mediated acetylation of C/EBPβ leads to enhanced C/EBPβ transactivation activity on the Arg1 promoter subsequently enhancing Arg1 expression, and pharmacological inhibition of p300 led to reduced MDSC immunosuppressive activity and tumour burden in vivo.